|
|
Parkinson's
Disease
Biomarkers | |
Levels of α-synuclein
monomer and its oligomeric, aggregated and phosphorylated forms are well known
to change in Parkinson’s Disease. An excellent review by Parnetti et al. (2019), published in Lancet Neurology,
discusses the Biomarker potential of α-synuclein isoforms and their clinical
utility.
Biosensis is addressing
the need for reliable and accurate quantification of α-synuclein by releasing
its NEW RapidTM ELISA Kit for this important
target (BEK-2216). It represents the first assay
in Biosensis’ collection of α-synuclein ELISA kits, with more kits in
development!
| |
Our new α-synuclein RapidTM ELISA Kit features:
· Real validation data on accurate quantification in human blood and CSF
· Low intra- and inter-assay CVs of < 10%
· Complete kit with precise instructions
· Fast (< 4 hours) and reliable assay performance
